ADCYAP1R1 and migraine disorder: In preclinical studies, AMG 301 has been shown to inhibit stimulus-evoked nociceptive activity in the TNC and the results are comparable to the inhibition observed with sumatriptan, supporting the role of PAC1 receptor in migraine pathophysiology.